查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2014449

DNA检测套组市场：按检测类型、技术、产品类型和最终用户划分－全球市场预测（2026-2032年）

DNA Test Kits Market by Test Type, Technology, Product Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年DNA检测套组市场价值为13.5亿美元，预计到2026年将成长至16.1亿美元，复合年增长率为19.49%，到2032年将达到46.9亿美元。

主要市场统计数据
基准年 2025 13.5亿美元
预计年份：2026年 16.1亿美元
预测年份 2032 46.9亿美元
复合年增长率 (%) 19.49%

DNA检测套组的策略性引入：消费者购买因素、临床检验流程、法规环境和商业化考量

DNA检测套组市场正处于技术快速发展和用户期望不断变化交汇的阶段，这给产品开发人员、临床采用者和销售团队带来了复杂的挑战。本文概述了影响该领域的关键因素，首先介绍了目前种类繁多的检测类型，从祖源和亲子鑑定到携带者筛检和高级健康风险评估。随着消费者对个人基因组学的兴趣日益增长，对临床级表现、可重复结果以及清晰的解读和后续流程的需求也随之增加。

在人工智慧、多组体学、消费者赋权和不断发展的数据管治的推动下，DNA 检测正在迅速从研究转向常规医疗保健。

DNA检测套组的市场格局正经历一场变革性的转变，重塑着供需动态。技术融合，特别是高通量定序和先进分析技术的整合，使得以往仅限于专业实验室的检测方式得以进入更广泛的临床和消费管道。因此，DNA检测正从短暂的好奇心转变为预防医学和药物治疗决策中的实用环节。药物药物基因体学和遗传易感性评估在常规临床工作流程中日益增长的效用，进一步推动了这一发展趋势。

研究 2025 年美国关税对供应链、製造决策、监管协调和临床服务的累积影响。

美国在2025年实施的关税政策为DNA检测套组的生产和销售企业带来了新的业务限制，其累积影响波及采购、生产和服务交付等各个环节。进口试剂、耗材和专用设备的关税成本压力促使企业重新评估其供应商组合，并寻求替代筹资策略。为此，一些製造商加快了关键零件的在地采购，而另一些製造商则调整了定价模式，以维持利润率并继续投资研发。

整合测试类型、技术、产品类别和最终用户行为等关键细分洞察，对于制定有针对性的策略和发展至关重要。

精细化的市场区隔框架对于将多样化的使用者需求转化为产品和商业优先事项至关重要。就检测类型而言，市场涵盖祖源分析、携带者检测（进一步细分为筛检和产前携带者筛检）、健康风险检测（包括遗传疾病易感性检测）、生活方式和健康相关应用，以及药物基因体学和亲子鑑定服务（区分资讯性亲子鑑定和法律亲子鑑定）。每种检测类型都有其独特的临床效用、检体处理要求和监管要求，这些都体现在检验方法和讯息策略的製定中。

区域分析比较了美洲、欧洲、中东和非洲以及亚太地区，突显了监管差异、扩散模式和供应韧性。

区域趋势对DNA检测套组的研发、监管和商业化有显着影响，每个地区都拥有其独特的优势和限制因素。在美洲，强劲的消费者需求和完善的临床遗传学基础设施支撑着多元化的销售管道，涵盖从直接面向消费者销售到与医院检查室服务的整合。这种环境促进了快速创新和扩充性的分销，同时也要求仔细考虑支付方的要求以及各州之间细微的监管差异。

透过垂直整合、临床伙伴关係、智慧财产权管理和服务差异化，塑造 DNA检测套组公司的企业策略和合作伙伴关係。

DNA检测套组生态系统中的企业正透过结合技术领先优势、策略伙伴关係和营运整合来实现差异化竞争。市场领导和新兴挑战者都在寻求垂直整合，以确保关键试剂和设备的供应；而其他企业则专注于服务差异化，提供解读平台、临床医生支援服务和纵向数据产品。与临床检查室、医疗保健系统和数位健康平台的伙伴关係，能够扩大分销范围并加速临床检验流程。

为行业领导者提供实用建议，以优化产品蓝图、加强价值链、与监管机构合作以及使定价与临床价值保持一致。

产业领导者应采取一系列切实可行的措施，在保持临床可靠性和消费者信心的同时，实现长期价值。首先，应优先考虑模组化产品架构，使其能够在专业检测和自测模式之间快速切换，从而无需彻底重新设计即可应对不断变化的监管要求和用户偏好。其次，应透过策略性双重采购、库存避险以及关键试剂和耗材的选择性垂直整合来增强价值链韧性，从而最大限度地减少中断并保持交货性能。

这种高度透明的调查方法详细说明了初步访谈、二次检验验证、专家检验和品管，以确保调查方法的严谨性。

本报告基于多方面的研究途径，整合了来自一手访谈的洞见、对二手文献的回顾以及系统的专家检验，以确保分析的严谨性。一手研究包括对实验室负责人、临床医生、采购经理和产品经理进行详细访谈，以了解营运限制和推广应用的驱动因素。这些定性资讯用于建构假设，并确定定量后续研究的优先领域。

为了帮助 DNA 检测领域的相关人员制定策略重点，我们综合考虑了技术、监管和商业性因素，并得出了一些结论。

总之，本文整合了现代DNA检测套组开发和应用过程中涌现的技术、监管和商业性主题。定序和分析技术的进步不断扩展基因检测的临床效用，而日益严格的资料管治和监管审查也提高了证据产生的门槛。这些趋势共同作用，有利于那些能够将严谨的分析检验、以使用者为中心的报告和安全的资料管理结合的机构。

目录

第一章 引言

第二章 分析方法

  • 分析设计
  • 分析框架
  • 市场规模预测
  • 数据三角测量
  • 分析结果
  • 分析的前提条件
  • 分析的局限性

第三章执行摘要

  • 首席体验长的观点
  • 市场规模和成长趋势
  • 市占率分析（2025 年）
  • FPNV定位矩阵（2025）
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入（GTM）策略

第五章 市场洞察

  • 消费者分析与最终用户观点
  • 消费者体验基准测试
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 成本效益分析（ROI）和成本效益分析（CBA）

第六章：美国关税的累积影响（2025 年）

第七章：人工智慧（AI）的累积影响（2025 年）

第八章：DNA检测套组市场：依检测类型划分

  • 祖先
  • 基因带原检测
    • 怀孕前携带者筛检
    • 产前携带者筛检
  • 健康风险
    • 易患遗传性疾病
    • 生活方式与健康
    • 药物基因体学
  • 亲子鑑定
    • 亲子鑑定仅用于提供信息
    • 亲子鑑定

第九章：DNA检测套组市场：依技术划分

  • 微阵列
  • PCR
  • 定序

第十章：DNA检测套组市场：依产品类型划分

  • 商用套件
    • 临床诊断试剂盒
    • 研究工具包
  • 自测检测套组

第十一章 DNA检测套组市场：依最终用户划分

  • 一般消费者
  • 医护人员
    • 诊断和检测机构
    • 医院、诊所
  • 研究机构

第十二章 DNA检测套组市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 DNA检测套组市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 DNA检测套组市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国DNA检测套组市场

第十六章：中国DNA检测套组市场

第十七章 竞争格局

  • 市场集中度分析（2025 年）
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析（2025 年）
  • 产品系列分析（2025 年）
  • 基准分析（2025 年）
  • 23andMe, Inc.
  • AB ANALITICA srl
  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Ancestry.com LLC
  • Bio-Rad Laboratories, Inc.
  • BioNano Genomics, Inc.
  • CyberGene AB
  • FitnessGenes Limited
  • FUTURA GENETICS
  • Illumina, Inc.
  • Indus Health Plus Pvt Ltd
  • Living DNA Ltd,
  • MyHeritage Ltd.
  • Premas Lifesciences Pvt. Ltd.
  • QIAGEN NV
  • Roche Diagnostics
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific
  • Veritas Genetics International Limited
Product Code: MRR-4348D129FA45

The DNA Test Kits Market was valued at USD 1.35 billion in 2025 and is projected to grow to USD 1.61 billion in 2026, with a CAGR of 19.49%, reaching USD 4.69 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.35 billion
Estimated Year [2026] USD 1.61 billion
Forecast Year [2032] USD 4.69 billion
CAGR (%) 19.49%

Strategic introduction to DNA test kits examining consumer drivers, clinical validation pathways, regulatory context and commercialization considerations

The DNA test kit landscape is at the intersection of rapid technological progress and shifting user expectations, creating a complex environment for product developers, clinical adopters and commercial teams. This introduction frames the critical forces shaping the sector, beginning with the broad spectrum of test types that now extend from ancestry and paternity to carrier screening and sophisticated health-risk assessments. As consumer interest in personal genomics grows, so does the demand for clinical-grade performance, reproducible results, and clear pathways for interpretation and follow-up.

In parallel, technology choices-from microarrays to PCR workflows and sequencing platforms-determine not only analytic sensitivity but also cost structure, throughput and the potential for downstream integration with electronic health systems. Product strategies must account for the divergent needs of professional users, including clinical diagnostic laboratories and research institutions, as well as self-testing markets where ease of use and privacy assurances dominate decision criteria. Transitioning from prototype to market requires careful navigation of regulatory expectations, lab accreditation standards and payer perspectives, all while maintaining a focus on data security.

Throughout this report, the introduction establishes the conceptual framework used to evaluate innovations, competitive dynamics and commercial viability. It emphasizes the need for clear analytical validation, robust operational design and alignment between product claims and user expectations to ensure long-term adoption and trust in genetic testing.

Rapid transformative shifts reshaping DNA testing from research to routine care driven by AI, multi-omics, consumer empowerment and evolving data governance

The landscape of DNA test kits is undergoing transformative shifts that reconfigure both supply and demand dynamics. Technological convergence, particularly the integration of higher-throughput sequencing and advanced analytics, is enabling test formats that were previously confined to specialist laboratories to enter broader clinical and consumer channels. As a result, testing is moving from episodic curiosity toward actionable components of preventive care and pharmacotherapy decision making. This evolution is reinforced by the rising utility of pharmacogenomics and genetic predisposition assessments in routine clinical workflows.

Concurrently, artificial intelligence and machine learning are improving variant interpretation and phenotype linkage, creating opportunities to package more insightful, clinician-friendly reports. These gains are tempered by heightened attention to data governance and privacy, which are prompting firms to adopt more rigorous consent frameworks and secure data handling practices. Regulatory attention is intensifying as agencies refine guidance on direct-to-consumer disclosures and clinical claims, which increases the premium on validated evidence and transparent performance metrics.

Finally, consumer expectations have shifted toward integrated services that combine testing with counseling, longitudinal follow-up and digital health interfaces. This creates a strategic imperative for firms to form cross-sector collaborations spanning clinical networks, payers and digital health platforms, enabling an end-to-end experience that bridges raw data and actionable recommendations while maintaining trust and clinical relevance.

Exploration of cumulative effects from United States tariffs in 2025 on supply chains, manufacturing decisions, regulatory alignment and clinical service

United States tariff actions in 2025 introduced a new operating constraint for companies producing and distributing DNA test kits, with cumulative effects that ripple across procurement, manufacturing and service delivery. Tariff-induced cost pressures on imported reagents, consumables and specialized instrumentation have incentivized firms to reassess supplier portfolios and pursue alternative sourcing strategies. In response, some manufacturers accelerated localization of critical components while others restructured pricing models to preserve margins and sustain R&D investments.

Supply chain adjustments have also affected inventory strategies and lead-time management, prompting a shift toward dual sourcing and increased onshore inventory buffers for mission-critical items. These operational changes have implications for turnaround times and laboratory throughput, and have elevated contract management as a core capability. At the same time, tariffs have catalyzed conversations with regulators and payers about the downstream impact on access and affordability, especially where cost increases could deter clinician ordering or consumer uptake.

Strategically, the tariff environment has accentuated the importance of design-for-manufacturability choices that reduce dependence on tariff-exposed inputs, and it has increased the appeal of vertically integrated models that control more of the value chain. In short, the tariff landscape of 2025 has been a catalyst for supply chain resilience strategies, procurement diversification and closer alignment between commercial pricing and operational realities.

Key segmentation insights synthesizing test types, technologies, product classifications and end user behaviors to shape targeted strategies and development

A nuanced segmentation framework is essential to translate heterogeneous user needs into product and commercial priorities. Considering test type, the market spans ancestry assays, carrier testing segmenting further into preconception carrier screening and prenatal carrier screening, health risk testing that includes genetic disease predisposition, lifestyle and wellness applications as well as pharmacogenomics, and paternity offerings that differentiate informational paternity from legal paternity scenarios. Each test type carries distinct clinical utility, sample handling requirements and regulatory expectations, which inform validation approaches and messaging strategies.

Technology choice similarly shapes performance and cost trade-offs. Microarray platforms offer efficient genotyping for targeted applications, PCR methods provide rapid, focused assays suited to single-gene or targeted variant detection, and sequencing technologies enable comprehensive variant discovery and copy-number resolution for broader clinical interpretations. Product type segmentation separates professional use kits-further divided into clinical diagnostics kits and research use only kits-from self-testing kits, creating divergent product development pathways and distribution channels.

End user distinctions influence packaging, service levels and commercialization approaches. Individual consumers require clarity, privacy assurances and simplified reporting, while medical professionals, including diagnostic laboratories and hospitals and clinics, demand rigorous analytic validation, chain-of-custody controls and integration with clinical workflows. Research institutes prioritize modularity and data access for hypothesis-driven studies. Mapping these dimensions against one another reveals where clinical demand, regulatory burden and commercial opportunity align, guiding prioritization for R&D, pricing and market entry strategies.

Regional insights comparing Americas, Europe Middle East and Africa, and Asia-Pacific to highlight regulatory variation, adoption patterns and supply resilience

Regional dynamics significantly influence how DNA test kits are developed, regulated and commercialized, with each geography presenting unique advantages and constraints. In the Americas, robust consumer demand and established clinical genetics infrastructure support diverse channels from direct-to-consumer offerings to integrated hospital laboratory services. This environment rewards rapid innovation and scalable distribution, but also requires careful navigation of payer requirements and state-level regulatory nuances.

In Europe, Middle East & Africa, the regulatory and reimbursement landscape displays substantial variation across countries, which encourages localized regulatory strategies and region-specific evidence generation to support clinical adoption. Data protection standards and cross-border data transfer considerations are particularly salient, prompting firms to invest in compliant data architectures and localized interpretation services. Supply chain pathways and reimbursement models in this region often call for flexible commercial approaches that can adapt to diverse health system structures.

Asia-Pacific exhibits a mix of market maturity, with some markets characterized by strong government-led genomic initiatives and others by rapidly growing consumer segments. Manufacturing capacity in the region has been expanding, offering opportunities to source components closer to end markets and to partner with regional clinical networks for validation studies. Across all regions, success depends on aligning technical validation and regulatory submissions with local expectations while tailoring go-to-market models to account for variations in clinician behavior, consumer trust and reimbursement mechanisms.

Corporate strategies and alliances shaping DNA test kit companies through vertical integration, clinical partnerships, IP stewardship and service differentiation

Companies operating in the DNA test kit ecosystem are differentiating through a combination of technology leadership, strategic partnerships and operational integration. Market leaders and emerging challengers alike are pursuing vertical integration to secure supply of critical reagents and instrumentation, while others focus on service differentiation by offering interpretation platforms, clinician support services and longitudinal data products. Partnerships with clinical laboratories, healthcare systems and digital health platforms amplify distribution reach and accelerate clinical validation pathways.

Intellectual property stewardship remains a core strategic asset, influencing competitive positioning and licensing strategies. Firms that balance proprietary assay development with interoperable reporting standards often find broader clinical adoption. Additionally, pricing strategies are evolving to reflect bundled service models where testing is paired with counseling, follow-up care or integration into digital care pathways. This shift increases the emphasis on demonstrating clinical and economic value to payers and providers.

Mergers and acquisitions continue to be a consolidation mechanism for capabilities such as bioinformatics, sample logistics and regulatory expertise. Companies that invest in scalable laboratory operations, robust quality management systems and data governance frameworks are better positioned to translate scientific advances into reliable, reproducible products that meet the diverse needs of clinical and consumer markets.

Actionable recommendations for industry leaders to optimize product roadmaps, strengthen supply chains, engage regulators and align pricing to clinical value

Industry leaders should adopt a pragmatic set of actions to capture long-term value while preserving clinical credibility and consumer trust. First, prioritize modular product architectures that allow rapid adaptation between professional and self-testing formats, enabling firms to respond to changing regulatory requirements and user preferences without full redesign. Second, strengthen supply chain resilience through strategic dual sourcing, inventory hedging and selective vertical integration for critical reagents and consumables to minimize disruption and preserve fulfillment performance.

Third, engage proactively with regulators and payers by generating clinical utility evidence and economic narratives that connect test results to actionable care pathways. Early engagement helps clarify submission expectations and accelerates coverage conversations. Fourth, invest in secure, privacy-first data platforms and transparent consent models that build user confidence and facilitate appropriate data sharing for research and clinical follow-up. Fifth, pursue partnerships that expand clinical validation opportunities, such as collaborations with diagnostic laboratories and specialty clinics, to accelerate adoption and incorporate clinician feedback into product refinement.

Finally, align commercial models to demonstrate clear value to clinicians and consumers, using outcome-based narratives where possible. These combined steps will help organizations balance near-term operational challenges with sustainable positioning for the ongoing clinical integration of genomic testing.

Transparent research methodology detailing primary interviews, secondary triangulation, expert validation and quality controls to ensure methodological rigor

This report is grounded in a multi-method research approach that integrates primary interview insights, secondary literature review and systematic expert validation to ensure analytical rigor. Primary research included in-depth interviews with laboratory directors, clinicians, procurement leaders and product managers to capture real-world operational constraints and adoption drivers. These qualitative inputs informed hypothesis generation and prioritized areas for quantitative follow-up.

Secondary research synthesized peer-reviewed literature, regulatory guidance documents and company disclosures to map technology attributes, validation expectations and product archetypes. Data triangulation techniques reconciled divergent findings from multiple sources, and analytic frameworks were applied to segment the market along test type, technology, product type and end user dimensions. Expert panels provided critical review of assumptions, ensuring that interpretive judgments aligned with current practice and emerging trends.

Quality control procedures included cross-checking technical claims, validating terminology consistency across regions and documenting methodological limitations. Where data gaps existed, the methodology identifies recommended follow-up studies and bespoke analyses that can refine strategic decisions. The approach is designed to be transparent and reproducible, supporting confident application of insights to product development, regulatory planning and go-to-market execution.

Concluding perspectives synthesizing technological, regulatory and commercial drivers to inform strategic priorities for stakeholders in DNA testing

The conclusion integrates the technological, regulatory and commercial themes that emerge from contemporary DNA test kit development and deployment. Advances in sequencing and analytics are broadening the clinical utility of genetic testing, while increased scrutiny on data governance and regulatory claims is raising the bar for evidence generation. Together, these dynamics favor organizations that combine rigorous analytic validation with user-centered reporting and secure data practices.

Commercially, success will hinge on demonstrating clinical relevance through partnerships with laboratories and health systems, and on developing commercial models that align price with demonstrated outcomes. Operational resilience-particularly in supply chain design and component sourcing-remains a critical determinant of sustained service quality. Regional heterogeneity requires tailored regulatory strategies and localized engagement plans to translate global capabilities into local adoption.

In sum, stakeholders who integrate technical excellence, regulatory foresight and pragmatic commercial execution will be best positioned to translate genomic innovation into repeatable, scalable clinical and consumer services. The strategic priorities identified here provide a roadmap for converting scientific promise into durable market impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. DNA Test Kits Market, by Test Type

  • 8.1. Ancestry
  • 8.2. Carrier Testing
    • 8.2.1. Preconception Carrier Screening
    • 8.2.2. Prenatal Carrier Screening
  • 8.3. Health Risk
    • 8.3.1. Genetic Disease Predisposition
    • 8.3.2. Lifestyle And Wellness
    • 8.3.3. Pharmacogenomics
  • 8.4. Paternity
    • 8.4.1. Informational Paternity
    • 8.4.2. Legal Paternity

9. DNA Test Kits Market, by Technology

  • 9.1. Microarray
  • 9.2. PCR
  • 9.3. Sequencing

10. DNA Test Kits Market, by Product Type

  • 10.1. Professional Use Kits
    • 10.1.1. Clinical Diagnostics Kits
    • 10.1.2. Research Use Only Kits
  • 10.2. Self Testing Kits

11. DNA Test Kits Market, by End User

  • 11.1. Individuals
  • 11.2. Medical Professionals
    • 11.2.1. Diagnostic Laboratories
    • 11.2.2. Hospitals And Clinics
  • 11.3. Research Institutes

12. DNA Test Kits Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. DNA Test Kits Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. DNA Test Kits Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States DNA Test Kits Market

16. China DNA Test Kits Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 23andMe, Inc.
  • 17.6. AB ANALITICA srl
  • 17.7. Abbott Laboratories
  • 17.8. Agilent Technologies Inc.
  • 17.9. Ancestry.com LLC
  • 17.10. Bio-Rad Laboratories, Inc.
  • 17.11. BioNano Genomics, Inc.
  • 17.12. CyberGene AB
  • 17.13. FitnessGenes Limited
  • 17.14. FUTURA GENETICS
  • 17.15. Illumina, Inc.
  • 17.16. Indus Health Plus Pvt Ltd
  • 17.17. Living DNA Ltd,
  • 17.18. MyHeritage Ltd.
  • 17.19. Premas Lifesciences Pvt. Ltd.
  • 17.20. QIAGEN N.V.
  • 17.21. Roche Diagnostics
  • 17.22. Siemens Healthcare GmbH
  • 17.23. Thermo Fisher Scientific
  • 17.24. Veritas Genetics International Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL DNA TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DNA TEST KITS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DNA TEST KITS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DNA TEST KITS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DNA TEST KITS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DNA TEST KITS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DNA TEST KITS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DNA TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DNA TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DNA TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DNA TEST KITS MARKET SIZE, BY ANCESTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DNA TEST KITS MARKET SIZE, BY ANCESTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DNA TEST KITS MARKET SIZE, BY ANCESTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DNA TEST KITS MARKET SIZE, BY PRECONCEPTION CARRIER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DNA TEST KITS MARKET SIZE, BY PRECONCEPTION CARRIER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DNA TEST KITS MARKET SIZE, BY PRECONCEPTION CARRIER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DNA TEST KITS MARKET SIZE, BY PRENATAL CARRIER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DNA TEST KITS MARKET SIZE, BY PRENATAL CARRIER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DNA TEST KITS MARKET SIZE, BY PRENATAL CARRIER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DNA TEST KITS MARKET SIZE, BY HEALTH RISK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DNA TEST KITS MARKET SIZE, BY HEALTH RISK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DNA TEST KITS MARKET SIZE, BY HEALTH RISK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DNA TEST KITS MARKET SIZE, BY GENETIC DISEASE PREDISPOSITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DNA TEST KITS MARKET SIZE, BY GENETIC DISEASE PREDISPOSITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DNA TEST KITS MARKET SIZE, BY GENETIC DISEASE PREDISPOSITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DNA TEST KITS MARKET SIZE, BY LIFESTYLE AND WELLNESS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DNA TEST KITS MARKET SIZE, BY LIFESTYLE AND WELLNESS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DNA TEST KITS MARKET SIZE, BY LIFESTYLE AND WELLNESS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DNA TEST KITS MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DNA TEST KITS MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DNA TEST KITS MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DNA TEST KITS MARKET SIZE, BY PATERNITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DNA TEST KITS MARKET SIZE, BY PATERNITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DNA TEST KITS MARKET SIZE, BY PATERNITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DNA TEST KITS MARKET SIZE, BY INFORMATIONAL PATERNITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DNA TEST KITS MARKET SIZE, BY INFORMATIONAL PATERNITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DNA TEST KITS MARKET SIZE, BY INFORMATIONAL PATERNITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DNA TEST KITS MARKET SIZE, BY LEGAL PATERNITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DNA TEST KITS MARKET SIZE, BY LEGAL PATERNITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DNA TEST KITS MARKET SIZE, BY LEGAL PATERNITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DNA TEST KITS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DNA TEST KITS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DNA TEST KITS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DNA TEST KITS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DNA TEST KITS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DNA TEST KITS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DNA TEST KITS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DNA TEST KITS MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DNA TEST KITS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DNA TEST KITS MARKET SIZE, BY CLINICAL DIAGNOSTICS KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DNA TEST KITS MARKET SIZE, BY CLINICAL DIAGNOSTICS KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DNA TEST KITS MARKET SIZE, BY CLINICAL DIAGNOSTICS KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DNA TEST KITS MARKET SIZE, BY RESEARCH USE ONLY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DNA TEST KITS MARKET SIZE, BY RESEARCH USE ONLY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DNA TEST KITS MARKET SIZE, BY RESEARCH USE ONLY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DNA TEST KITS MARKET SIZE, BY SELF TESTING KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DNA TEST KITS MARKET SIZE, BY SELF TESTING KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DNA TEST KITS MARKET SIZE, BY SELF TESTING KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DNA TEST KITS MARKET SIZE, BY INDIVIDUALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DNA TEST KITS MARKET SIZE, BY INDIVIDUALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DNA TEST KITS MARKET SIZE, BY INDIVIDUALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DNA TEST KITS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DNA TEST KITS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DNA TEST KITS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DNA TEST KITS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DNA TEST KITS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DNA TEST KITS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DNA TEST KITS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DNA TEST KITS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DNA TEST KITS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DNA TEST KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS DNA TEST KITS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA DNA TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA DNA TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA DNA TEST KITS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE DNA TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST DNA TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA DNA TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC DNA TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL DNA TEST KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN DNA TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 172. GCC DNA TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GCC DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 175. GCC DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 176. GCC DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 177. GCC DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. GCC DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 180. GCC DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. GCC DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION DNA TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS DNA TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 202. G7 DNA TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. G7 DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. G7 DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 205. G7 DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 206. G7 DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 207. G7 DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. G7 DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 210. G7 DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. G7 DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 212. NATO DNA TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. NATO DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 215. NATO DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 216. NATO DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 217. NATO DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. NATO DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. NATO DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 220. NATO DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. NATO DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL DNA TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES DNA TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA DNA TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)